Guide to buying DexCom stock in Canada

DexCom is a medical devices business based in the US. DexCom stocks (DXCM) are listed on the NASDAQ, and all prices are listed in US Dollars.

Its last market close was $63.47, which is an increase of 5.38% over the previous week. DexCom employs 10,200 staff and has a trailing 12-month revenue of around $4.5 billion.

Keep reading to see up-to-date DexCom stock price and performance data, along with a step-by-step guide for how to buy DexCom stock in Canada.

DexCom (DXCM) stock summary

Company stock name	DexCom Inc
Stock ticker symbol	DXCM
Exchange	NASDAQ
Open	$62.57
High	$63.95
Low	$62.23
Close	$63.47
Adjusted closing	$63.47
Volume The number of stocks traded during the day	2,254,800
52-week stock price range	$54.11 – $93.25
Where to buy DexCom stock	Buy on CIBC Investor's Edge

The values in this table are accurate as of the market close on November 27, 2025, and all amounts are in USD.

Can I buy DexCom stock in Canada?

Yes, you can buy DexCom stock in Canada. You simply need to open a brokerage account with an online trading platform that supports stocks on the NASDAQ exchange. Platforms like Interactive Brokers will allow you to directly buy DexCom stock from within Canada.

Dive deeper: Detailed guide on how to buy stocks in Canada

Our top picks for where to buy DexCom stock

DexCom stock chart (NASDAQ: DXCM)

This chart tracks DexCom stock price performance over time.

DexCom stock price

DexCom's stock price at the last available market close was $63.47 (as of November 27, 2025). Keep in mind that DexCom's stock price can be impacted on a daily, or even hourly, basis by factors like company performance, the broader economy and investor sentiments.

Is DexCom stock a buy or sell right now?

The technical analysis gauge above shows real-time buy or sell ratings and analysis for DexCom stock based on your selected timeframe. It uses three widely followed indicators—moving averages, oscillators and pivots—but this does not represent investment advice or a guarantee of success. Finder may not concur with these signals and accepts no responsibility for the performance of your stocks.

Can I buy DexCom stock on the TSX?

No, you cannot buy DexCom stock on the TSX because DexCom stock is not listed on the TSX. Instead, DexCom stock is listed on the NASDAQ under the symbol "DXCM."

That said, if you're wondering how to invest in DexCom stock in Canada, you still have the option to do so by opening a trading account with a Canadian brokerage that gives you access to NASDAQ, like Interactive Brokers.

Dive deeper: Our picks for the best stocks to buy right now in Canada

DexCom stock dividends

DexCom is not expected to pay a dividend over the next 12 months. We'll continue to monitor DexCom's stock information and update this guide if that changes.

DexCom stock performance metrics

Here are some common key metrics for DexCom stock that analysts often use to help gauge a stock's value—P/E ratio, PEG ratio and EBITDA.

• DexCom's P/E ratio

  DexCom's current share price divided by its per-share earnings (EPS) over the past 12 months gives a trailing price/earnings (P/E) ratio of roughly 33x. In other words, DexCom shares trade at around 33 times recent earnings.

  That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the stock or simply that they're over-valued.

• DexCom's PEG ratio

  DexCom's price/earnings-to-growth (PEG) ratio is calculated by dividing its P/E ratio by its earnings growth, which comes out to about 0.7691. A lower ratio can suggest a stock offers better value, while a higher ratio may suggest worse value.

  The PEG ratio provides a broader view than the P/E ratio alone, as it factors in DexCom's expected earnings growth. By accounting for growth, investors can use the PEG ratio to compare the valuations of multiple high-growth companies.

• DexCom's EBITDA

  DexCom's EBITDA (earnings before interest, taxes, depreciation and amortization) is $1 billion. EBITDA is a measure of a company's overall financial performance and is often used as a proxy for a company's profitability.

Has DexCom stock ever split?

DexCom's stocks were split on a 4:1 basis on June 12, 2022. So, if you had owned 1 share the day before before the split, the next day you'd have owned 4 shares. This wouldn't directly have changed the overall worth of your DexCom stocks, just the quantity.

However, indirectly, the new 75% lower stock price could have impacted the market appetite for DexCom stocks, which in turn could have impacted DexCom's stock price.

How volatile is DexCom stock?

Over the last 12 months, DexCom's stocks price has ranged from $54.11 to as high as $93.25. DexCom's beta measurement of stock volatility is 1.52. For comparison, the market () average beta is 1. This would suggest that DexCom's stocks are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Some analysists use "beta" to gauge a stock's volatility. Beta is a popular way to measure a stocks volatility in relation to the market. Here is a breakdown of DexCom's beta stock volatility rating.

DexCom Inc company and revenue performance

Market Capitalization The total market value of DexCom's outstanding shares	$23.6 billion
Gross profit (TTM)	$2.7 billion
Operating margin (TTM)	20.05%
Profit margin	15.96%
Revenue (TTM)	$4.5 billion
Return on assets (TTM)	7.02%
Return on equity (TTM)	30.64%
Earnings per share (TTM)	$1.80
50-day moving stock price average The average share price over the last 50 days	$65.50
200-day moving stock price average The average share price over the last 200 days	$76.13

All dollar amounts in this table are in USD. TTM refers to the "trailing 12 months." All values are accurate as of the market close on November 27, 2025.

DexCom company profile

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians.

Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products.

It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

• Common company-related questions about DexCom

  What percentage of DexCom is owned by insiders or institutions?
  Currently 0.418% of DexCom stocks are held by insiders and 98.838% by institutions.

  How many people work for DexCom?
  Latest data suggests 10,200 work at DexCom.

  When does the fiscal year end for DexCom?
  DexCom's fiscal year ends in December.

  Where is DexCom based?
  DexCom's address is: 6340 Sequence Drive, San Diego, CA, United States, 92121

  What is DexCom's ISIN number?
  DexCom's international securities identification number is: US2521311074

  What is DexCom's CUSIP number?
  DexCom's Committee on Uniform Securities Identification Procedures number is: 252131107

Compare trading platforms to buy DexCom stock

Compare special offers, low fees and a wide range of investment options among popular trading platforms in Canada. Note that the dollar amounts in the table below are in CAD.

Related: Compare the best stock trading platforms in Canada

Do I have to pay tax on gains from DexCom stock sales in Canada?

Yes, you'll need to pay taxes in Canada on investment income, which includes any profit from selling DexCom stock. The CRA taxes investment income from stocks in Canada based on three main factors:

1. Investment income. Investment income includes money earned from interest, dividends or capital gains, which may affect how much you have to pay in taxes on stock sales in Canada.
2. Investor type. Your investment income will be taxed differently depending on whether you're a regular investor or a day trader (which means you buy and trade stocks on a daily basis as your primary form of income).
3. Tax bracket. The higher your tax bracket, the more you'll pay on income from stock sales. Your tax bracket depends on your gross income (minus deductions).

You can learn more about the tax implications of selling stocks in Canada here.

Frequently asked questions about DexCom stock

• Can I buy DexCom stock directly as a Canadian investor?

  Yes, Canadian investors can buy DexCom stock directly through various online brokerage platforms available in Canada. You can compare trading platform options and fees for buying DexCom stock in our table here.

• How much is DexCom stock worth?

  As of the last market close (on November 27, 2025), DexCom stock is worth $63.47 per share.

• Can Canadians buy American stocks?

  Yes, Canadians can buy American stocks through Canadian trading platforms that give access to American stock exchanges such as the NYSE and Nasdaq. The good news is that most Canadian brokerage platforms, like Questrade, Interactive Brokers, Moomoo and Wealthsimple, give access to US exchanges. Read our full guide on how to buy US stocks in Canada to learn more.

• Can I buy fractional shares of DexCom stock?

  Yes, it may be possible to buy fractional shares of DexCom stock depending on the trading platform you're signed up with. Fractional shares can allow you to invest in DexCom stock even when you can't afford its full share price. You can read our full guide to how fractional shares work to learn more.

  The table below shows trading apps in Canada that offer fractional shares:

  Sort: Default

  Finder Score (low-high)Finder Score (high-low)Available Asset Types (low-high)Available Asset Types (high-low)Account Types (low-high)Account Types (high-low)Stock Trading Fee (low-high)Stock Trading Fee (high-low)Monthly Account Fee (low-high)Monthly Account Fee (high-low)

  3 of 3 results

  Finder Score	Available Asset Types	Account Types	Stock Trading Fee	Monthly Account Fee
  Promoted Finder Score 9.1 Excellent Questrade	Finder Score 9.1 Excellent	Stocks, Bonds, Options, Mutual Funds, Index Funds, ETFs, Forex, GICs, Precious Metals, IPOs	RRSP, RESP, RRIF, TFSA, Personal, Joint, FHSA	$0	$0	Get free contracts, no commissions and a 30 day free trial of Questrade Plus. Use offer code FREEOPTIONS. T&Cs apply.	Go to site More info Compare product selection Compare	loading
  Promoted Finder Score 8.8 Great Interactive Brokers	Finder Score 8.8 Great	Stocks, Bonds, Options, Index Funds, ETFs, Forex, Currencies, Futures	RRSP, TFSA, Personal, Joint	min $1.00, max 0.5%	$0	Go to site More info Compare product selection Compare	loading
  Finder Score 7.4 Great Moomoo Financial Canada	Finder Score 7.4 Great	Stocks, Options, ETFs	RRSP, TFSA, Personal, FHSA	$1.49/stock	$0	Enjoy a 6% cash rebate plus up to $4,600 in trading perks. Offer ends November 30, 2025. T&Cs apply.	Go to site More info Compare product selection Compare	loading

  loading

  Load more

  Showing1 - 3 of 3 results

  Finder Score for stock trading platforms

  To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score, the better the platform—it's that simple.

  Read the full methodology

Related: New to stock trading? Compare brokers and get tips for investing.

Important information: Powered by Finder.com. This information is general in nature and is no substitute for professional advice. It does not take into account your personal situation. This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for most investors. You do not own or have any interest in the underlying asset. Capital is at risk, including the risk of losing more than the amount originally put in, market volatility and liquidity risks. Past performance is no guarantee of future results. Tax on profits may apply. Consider the Product Disclosure Statement and Target Market Determination for the product on the provider's website. Consider your own circumstances, including whether you can afford to take the high risk of losing your money and possess the relevant experience and knowledge. We recommend that you obtain independent advice from a suitably licensed financial advisor before making any trades.